Vanda Pharmaceuticals Q3 2026 Earnings Date & Estimates

Vanda Pharmaceuticals (NASDAQ:VNDA) is a biopharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company was founded in 2003 and is headquartered in Washington, D.C. Its work centers on conditions involving sleep, circadian rhythms, and psychiatric health.

Vanda’s commercial products include Hetlioz (tasimelteon), a melatonin receptor agonist approved in the United States for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults. Vanda acquired U.S. rights to Fanapt from Novartis and is responsible for its commercialization in that market.

The company also maintains a development pipeline that has included investigational treatments for conditions such as gastroparesis and motion sickness. Vanda’s commercial activities have primarily focused on the United States, while its research and development efforts address potential opportunities in broader markets. Mihael H. Polymeropoulos, M.D., is Vanda’s founder, president and chief executive officer.